Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$MCET .0008 Volume: 74,568,806 Volumes GOES UP!!!
$MCET .0008 Volume: 74,568,806 Volumes GOES UP!!!
Attention: We're not talking about a takeover here!!!!! No merger! No takeover!
Multicell Technologies is an AMERICAN COMPANY! And not Germans!!!! WEBSITE IS FAKE!!!!!
For me it is about facts or even said truths, and that's why I take the time for them as best I can. Facts are based on searches on the Internet. Because of the MCET website, I don't believe in that at all. How so? Truth???? AND THAT'S MY OPINION!
Last quarter filings! 11/17/2019 Quarterly Report - Quarterly Report Q3 2019 Supplemental
>>>>> 5) Issuer’s Business, Products and Services <<<<<
https://backend.otcmarkets.com/otcapi/company/financial-report/234964/content
$MWXRF Mineworx Announces Rights Offering and Proposed Share Consolidation
SURREY, British Columbia, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Mineworx Technologies Ltd., (the "Corporation" or "Mineworx") (TSXV: MWX) (OTCQB: MWXRF) (FSE: YRS WKN: A2DSW3) announced that it will be offering rights (the "Rights Offering") to holders of its common shares ("Common Shares") of record at the close of business on January 28, 2021 (the “Record Date”). Pursuant to the Rights Offering, each holder of Common Shares (a “Shareholder”) will receive one (1) transferable right (each, a “Right”) for each Common Share held as of the Record Date. One (1) Right will entitle the holder thereof to subscribe for one Common Share upon payment of the subscription price of $0.015 per Common Share until 5:00 p.m. (Toronto time) (the “Expiry Time”) on March 8, 2021. Assuming the exercise of all Rights, the Rights Offering will raise gross proceeds of up to $4,841,476.
The Rights will be offered to Shareholders resident in each province and territory of Canada (the “Eligible ?Jurisdictions”) and Shareholders who have satisfied the requirements of the Corporation for those resident ?outside of the Eligible Jurisdictions. Accordingly, and subject to the detailed provisions of the right offering circular dated January 22, 2021 (the “Circular”), Rights ?certificates (“Rights Certificates”) will not be mailed to Shareholders resident outside of the Eligible ?Jurisdictions, unless such Shareholders are able to establish to the satisfaction of the Corporation, on or before ?February 26, 2021, that they are eligible to participate in the Rights Offering.? Shareholders who fully exercise their Rights will be entitled to subscribe for additional Common Shares, if ?available, that were not subscribed for by other holders of Rights prior to the Expiry Time.
The Corporation understands that certain directors and officers of the Corporation who own Common Shares intend to exercise their rights to purchase Common Shares under the Rights Offering.
The Corporation currently has 322,765,080 Common Shares issued and outstanding. If all Rights issued under the Rights Offering are validly exercised, an additional 322,765,080 Common Shares would be issued. The net proceeds from the Rights Offering will be used for capital expenditures and for general corporate purposes. The Rights Offering is subject to regulatory approval, including the final approval of the TSX Venture Exchange (the “TSXV”).
The Rights will be listed and posted for trading on the TSXV under the symbol “MWX.RT” on a “when issued” basis commencing on January 27, 2021 and will expire at 12:00 p.m. (Toronto time) on March 8, 2021.
Complete details of the Rights Offering are set out in the Circular and the rights offering notice (the ??“Notice”), which are filed under the Corporation’s profile at www.sedar.com. Registered Shareholders who wish to exercise their Rights must ?complete and forward the Rights Certificate, together with applicable funds, to Computershare Investor ?Services Inc., the depositary for the Rights Offering, on or before the Expiry Time of the Rights Offering. ?Shareholders who own their Common Shares through an intermediary, such as a bank, trust Corporation, ?securities dealer or broker, will receive materials and instructions from their intermediary.?
Share Consolidation
Following the Rights Offering, the Corporation intends to consolidate its issued and outstanding Common Shares, subject to regulatory approval, including approval of the TSX Venture Exchange. The proposed basis for the share consolidation is one (1) post-consolidation Common Share for up to every two (2) pre-consolidation Common Shares (the "Share Consolidation"). Mineworx plans to hold a special meeting of shareholders for the purposes of voting on the Share Consolidation to be held on March 2, 2021. Further information about the Meeting and the Share Consolidation will be provided to the Corporation's shareholders in a Notice of Meeting and Management Information Circular, to be sent to shareholders following the record date for the Meeting.
Information Webinar
The Corporation is holding an information webinar to provide addition information on the Rights Offering through a webinar to be held on Tuesday January 26, 2021 at 2pm (MST)/ 4pm (EST). To register for the webinar please follow the attached link:
https://us02web.zoom.us/webinar/register/WN_AbfmzwMTT5yNPhnY9P98gQ
https://www.otcmarkets.com/stock/MWXRF/news/Mineworx-Announces-Rights-Offering-and-Proposed-Share-Consolidation?id=287151
$MWXRF Mineworx Announces Rights Offering and Proposed Share Consolidation
SURREY, British Columbia, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Mineworx Technologies Ltd., (the "Corporation" or "Mineworx") (TSXV: MWX) (OTCQB: MWXRF) (FSE: YRS WKN: A2DSW3) announced that it will be offering rights (the "Rights Offering") to holders of its common shares ("Common Shares") of record at the close of business on January 28, 2021 (the “Record Date”). Pursuant to the Rights Offering, each holder of Common Shares (a “Shareholder”) will receive one (1) transferable right (each, a “Right”) for each Common Share held as of the Record Date. One (1) Right will entitle the holder thereof to subscribe for one Common Share upon payment of the subscription price of $0.015 per Common Share until 5:00 p.m. (Toronto time) (the “Expiry Time”) on March 8, 2021. Assuming the exercise of all Rights, the Rights Offering will raise gross proceeds of up to $4,841,476.
The Rights will be offered to Shareholders resident in each province and territory of Canada (the “Eligible ?Jurisdictions”) and Shareholders who have satisfied the requirements of the Corporation for those resident ?outside of the Eligible Jurisdictions. Accordingly, and subject to the detailed provisions of the right offering circular dated January 22, 2021 (the “Circular”), Rights ?certificates (“Rights Certificates”) will not be mailed to Shareholders resident outside of the Eligible ?Jurisdictions, unless such Shareholders are able to establish to the satisfaction of the Corporation, on or before ?February 26, 2021, that they are eligible to participate in the Rights Offering.? Shareholders who fully exercise their Rights will be entitled to subscribe for additional Common Shares, if ?available, that were not subscribed for by other holders of Rights prior to the Expiry Time.
The Corporation understands that certain directors and officers of the Corporation who own Common Shares intend to exercise their rights to purchase Common Shares under the Rights Offering.
The Corporation currently has 322,765,080 Common Shares issued and outstanding. If all Rights issued under the Rights Offering are validly exercised, an additional 322,765,080 Common Shares would be issued. The net proceeds from the Rights Offering will be used for capital expenditures and for general corporate purposes. The Rights Offering is subject to regulatory approval, including the final approval of the TSX Venture Exchange (the “TSXV”).
The Rights will be listed and posted for trading on the TSXV under the symbol “MWX.RT” on a “when issued” basis commencing on January 27, 2021 and will expire at 12:00 p.m. (Toronto time) on March 8, 2021.
Complete details of the Rights Offering are set out in the Circular and the rights offering notice (the ??“Notice”), which are filed under the Corporation’s profile at www.sedar.com. Registered Shareholders who wish to exercise their Rights must ?complete and forward the Rights Certificate, together with applicable funds, to Computershare Investor ?Services Inc., the depositary for the Rights Offering, on or before the Expiry Time of the Rights Offering. ?Shareholders who own their Common Shares through an intermediary, such as a bank, trust Corporation, ?securities dealer or broker, will receive materials and instructions from their intermediary.?
Share Consolidation
Following the Rights Offering, the Corporation intends to consolidate its issued and outstanding Common Shares, subject to regulatory approval, including approval of the TSX Venture Exchange. The proposed basis for the share consolidation is one (1) post-consolidation Common Share for up to every two (2) pre-consolidation Common Shares (the "Share Consolidation"). Mineworx plans to hold a special meeting of shareholders for the purposes of voting on the Share Consolidation to be held on March 2, 2021. Further information about the Meeting and the Share Consolidation will be provided to the Corporation's shareholders in a Notice of Meeting and Management Information Circular, to be sent to shareholders following the record date for the Meeting.
Information Webinar
The Corporation is holding an information webinar to provide addition information on the Rights Offering through a webinar to be held on Tuesday January 26, 2021 at 2pm (MST)/ 4pm (EST). To register for the webinar please follow the attached link:
https://us02web.zoom.us/webinar/register/WN_AbfmzwMTT5yNPhnY9P98gQ
https://www.otcmarkets.com/stock/MWXRF/news/Mineworx-Announces-Rights-Offering-and-Proposed-Share-Consolidation?id=287151
$MCET .0008 Volume: 53,558,361 Today Target again over 100 Millions of volumes!!!
$MCET .0008 Volume: 53,558,361 Today Target again over 100 Millions of volumes!!!
CERTIFICATE OF DOCUMENT FILED / Statement Curing Delinquency Page 1-4. https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160969871
Get a certificate of good standing
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160969369
$IDGC 0.0008 +23.08% Volume: 50,826,906
$IDGC 0.0008 +23.08% Volume: 50,826,906
$MCET NAICS Code 541711 – Research and Development in Biotechnology
https://classcodes.com/lookup/naics-code-541711/
Definition of NAICS Code 541711: This U.S. industry comprises establishments primarily engaged in conducting biotechnology research and experimental development. Biotechnology research and experimental development involves the study of the use of microorganisms and cellular and biomolecular processes to develop or alter living or non-living materials. This research and development in biotechnology may result in development of new biotechnology processes or in prototypes of new or genetically-altered products that may be reproduced, utilized, or implemented by various industries.
You can also download your own copy of the complete 2017 NAICS Classification Manual. The NAICS Manual is updated every five years. The 2017 copy will be applicable until a new edition is produced in 2022.
Illustrative Examples of NAICS 541711
What are some examples of this code? The bulleted items below are illustrative examples of this classification.
Recombinant DNA research and experimental development laboratories
DNA technologies (e.g., microarrays) research and experimental development laboratories
Cloning research and experimental development laboratories
Protein engineering research and experimental development laboratories
Nucleic acid chemistry research and experimental development laboratories
Nanobiotechnologies research and experimental development laboratories
Cross Reference Guide for Code 541711
What codes are similar to this classification that might be a more applicable code? The cross-reference guide below displays the codes for other similar industries. Please review to find the most applicable classification.
Conducting research and experimental development in the physical, engineering, and life sciences (except biotechnology)–are classified in U.S. Industry NAICS 541712, Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology);
Providing veterinary testing services–are classified in Industry NAICS 541940, Veterinary Services; Providing physical, chemical, or other analytical testing services (except medical or veterinary), such as acoustics or vibration testing, calibration testing, electrical and electronic testing, geotechnical testing, mechanical testing, nondestructive testing, or thermal testing–are classified in Industry NAICS 541380, Testing Laboratories;
Manufacturing vaccines, toxoids, blood fractions, and culture media of plant or animal origin (except diagnostic use)–are classified in U.S. Industry NAICS 325414, Biological Product (except Diagnostic)
Manufacturing; and Manufacturing uncompounded medicinal chemicals and their derivatives (i.e., enzyme proteins and antibiotics for pharmaceutical use)–are classified in U.S. Industry NAICS 325411, Medicinal and Botanical Manufacturing.
Other Index Entries for NAICS 541711
The North American Industry Classification System contains multiple index entries that are each descriptive of the same code. The bulleted list below shows all applicable index entries (Current and former) that are associated with this classification. These index entries further elaborate on the scope of applicable industries that have already been defined at the top of this page.
Biotechnology research and development laboratories or service in botany
Biotechnology research and development laboratories or services
Biotechnology research and development laboratories or services in agriculture
Biotechnology research and development laboratories or services in bacteriology
Biotechnology research and development laboratories or services in biology
Biotechnology research and development laboratories or services in chemical sciences
Biotechnology research and development laboratories or services in entomology
Biotechnology research and development laboratories or services in environmental science
Biotechnology research and development laboratories or services in food science
Biotechnology research and development laboratories or services in genetics
Biotechnology research and development laboratories or services in health sciences
Biotechnology research and development laboratories or services in industrial research
Biotechnology research and development laboratories or services in the medical sciences
Biotechnology research and development laboratories or services in the physical sciences
Biotechnology research and development laboratories or services in the veterinary sciences
Cloning research and experimental development laboratories
DNA technologies (e.g., microarrays) research and experimental development laboratories
Nanobiotechnologies research and experimental development laboratories
Nucleic acid chemistry research and experimental development laboratories
Protein engineering research and experimental development laboratories
Recombinant DNA research and experimental development laboratories
Suggested Insurance Conversion Table for NAICS Code 541711
Looking for an insurance classification other than the North American Industry Classification System? If a company falls within the industry defined on this page, then the class codes mentioned below may be applicable. Please note that the bulleted cross-reference guide below is not authoritative. Users should have an insurance professional review to ensure proper insurance classification.
Status A - Active record NCAGE 481X3: MULTICELL TECHNOLOGIES, INC.
https://eportal.nspa.nato.int/AC135Public/CageTool/cage-view/481X3
$MCET NAICS Code 541711 – Research and Development in Biotechnology
https://classcodes.com/lookup/naics-code-541711/
Definition of NAICS Code 541711: This U.S. industry comprises establishments primarily engaged in conducting biotechnology research and experimental development. Biotechnology research and experimental development involves the study of the use of microorganisms and cellular and biomolecular processes to develop or alter living or non-living materials. This research and development in biotechnology may result in development of new biotechnology processes or in prototypes of new or genetically-altered products that may be reproduced, utilized, or implemented by various industries.
You can also download your own copy of the complete 2017 NAICS Classification Manual. The NAICS Manual is updated every five years. The 2017 copy will be applicable until a new edition is produced in 2022.
Illustrative Examples of NAICS 541711
What are some examples of this code? The bulleted items below are illustrative examples of this classification.
Recombinant DNA research and experimental development laboratories
DNA technologies (e.g., microarrays) research and experimental development laboratories
Cloning research and experimental development laboratories
Protein engineering research and experimental development laboratories
Nucleic acid chemistry research and experimental development laboratories
Nanobiotechnologies research and experimental development laboratories
Cross Reference Guide for Code 541711
What codes are similar to this classification that might be a more applicable code? The cross-reference guide below displays the codes for other similar industries. Please review to find the most applicable classification.
Conducting research and experimental development in the physical, engineering, and life sciences (except biotechnology)–are classified in U.S. Industry NAICS 541712, Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology);
Providing veterinary testing services–are classified in Industry NAICS 541940, Veterinary Services; Providing physical, chemical, or other analytical testing services (except medical or veterinary), such as acoustics or vibration testing, calibration testing, electrical and electronic testing, geotechnical testing, mechanical testing, nondestructive testing, or thermal testing–are classified in Industry NAICS 541380, Testing Laboratories;
Manufacturing vaccines, toxoids, blood fractions, and culture media of plant or animal origin (except diagnostic use)–are classified in U.S. Industry NAICS 325414, Biological Product (except Diagnostic)
Manufacturing; and Manufacturing uncompounded medicinal chemicals and their derivatives (i.e., enzyme proteins and antibiotics for pharmaceutical use)–are classified in U.S. Industry NAICS 325411, Medicinal and Botanical Manufacturing.
Other Index Entries for NAICS 541711
The North American Industry Classification System contains multiple index entries that are each descriptive of the same code. The bulleted list below shows all applicable index entries (Current and former) that are associated with this classification. These index entries further elaborate on the scope of applicable industries that have already been defined at the top of this page.
Biotechnology research and development laboratories or service in botany
Biotechnology research and development laboratories or services
Biotechnology research and development laboratories or services in agriculture
Biotechnology research and development laboratories or services in bacteriology
Biotechnology research and development laboratories or services in biology
Biotechnology research and development laboratories or services in chemical sciences
Biotechnology research and development laboratories or services in entomology
Biotechnology research and development laboratories or services in environmental science
Biotechnology research and development laboratories or services in food science
Biotechnology research and development laboratories or services in genetics
Biotechnology research and development laboratories or services in health sciences
Biotechnology research and development laboratories or services in industrial research
Biotechnology research and development laboratories or services in the medical sciences
Biotechnology research and development laboratories or services in the physical sciences
Biotechnology research and development laboratories or services in the veterinary sciences
Cloning research and experimental development laboratories
DNA technologies (e.g., microarrays) research and experimental development laboratories
Nanobiotechnologies research and experimental development laboratories
Nucleic acid chemistry research and experimental development laboratories
Protein engineering research and experimental development laboratories
Recombinant DNA research and experimental development laboratories
Suggested Insurance Conversion Table for NAICS Code 541711
Looking for an insurance classification other than the North American Industry Classification System? If a company falls within the industry defined on this page, then the class codes mentioned below may be applicable. Please note that the bulleted cross-reference guide below is not authoritative. Users should have an insurance professional review to ensure proper insurance classification.
Status A - Active record NCAGE 481X3: MULTICELL TECHNOLOGIES, INC.
https://eportal.nspa.nato.int/AC135Public/CageTool/cage-view/481X3
$MCET Multicell Technologies has two active programs! Commercial and Government Entity NCAGE481X3 and COMMERCIAL AND GOVERNMENT ENTITY PROGRAM CAGE481X3
NCAGE CODE 481X3: NCAGE Code Registration Status A - Active record
MULTICELL TECHNOLOGIES, INC. Last Updated 2020-02-26 04:18:07
https://cage.report/NCAGE/481X3
Status Active CAGE 481X3: MULTICELL TECHNOLOGIES, INC.
https://cage.dla.mil/Search/Details?id=894402
$MCET Multicell Technologies has two active programs! Commercial and Government Entity NCAGE481X3 and COMMERCIAL AND GOVERNMENT ENTITY PROGRAM CAGE481X3
NCAGE CODE 481X3: NCAGE Code Registration Status A - Active record
MULTICELL TECHNOLOGIES, INC. Last Updated 2020-02-26 04:18:07
https://cage.report/NCAGE/481X3
Status Active CAGE 481X3: MULTICELL TECHNOLOGIES, INC.
https://cage.dla.mil/Search/Details?id=894402
Big jumps here available!
Big jumps here available!
In 6 months there were 5 huge surcharges! The rest were normal small also purchase surcharges. Sell more than buy? Answer no. How so???????????????????????????
Return up to 8s! Up and down!
Today over 100 millions of volumes??? More movement!
Another day with a lot of volume! Movement!
Another day with a lot of volume! Movement!
$IDGC Subsidiaries Noveda Technologies, Inc. KEY FACTS $$$$$$$$$$
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160995172
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160995318
$IDGC Subsidiaries Noveda Technologies, Inc. KEY FACTS $$$$$$$$$$
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160995172
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160995318
$IDGC Absolutely Confirmed! For all! Please read the info!
Last quarter filings! 11/17/2019 Quarterly Report - Quarterly Report Q3 2019 Supplemental
>>>>> 5) Issuer’s Business, Products and Services <<<<<
https://backend.otcmarkets.com/otcapi/company/financial-report/234964/content
CERTIFICATE OF DOCUMENT FILED / Statement Curing Delinquency Page 1-4. https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160969871
Get a certificate of good standing
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160969369
The content is confirmed! IoT 4.0 and Noveda Technologies!
https://www.otcmarkets.com/stock/IDGC/news/ID-Global-Corp-Announces-Corporate-Update-Management-Structure-after-Acquisition-by-Liberty-Capital-Group-of-San-Diego?id=228525
https://www.otcmarkets.com/stock/IDGC/news/IDGC-Completes-Strategic-Investment-In-Noveda-Technologies?id=233617
Liberty Capital Group. has the leadership position! Idglobal corporation subsidiaries is Farallon, inc., Prestige Liquids, LLC and Noveda Technologies, Inc.
Makes Idglobal also profit on Farallon, Inc.? Please review! They have a great many contracts.
https://govtribe.com/vendors/farallon-inc-dot-89wm4
PDF FORMAT!
Select Download FAR Report to review the Representations and Certifications for FARALLON INC. <<<<<<<
Select Download FAR & DFARS Report to review the Representations and Certifications for FARALLON INC. <<<<<<<
https://beta.sam.gov/entity/081494822?keywords=%22Farallon%20Inc.%22&sort=-relevance&index=&is_active=true&page=1&status=active
$IDGC Absolutely Confirmed! For all! Please read the info!
Last quarter filings! 11/17/2019 Quarterly Report - Quarterly Report Q3 2019 Supplemental
>>>>> 5) Issuer’s Business, Products and Services <<<<<
https://backend.otcmarkets.com/otcapi/company/financial-report/234964/content
CERTIFICATE OF DOCUMENT FILED / Statement Curing Delinquency Page 1-4. https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160969871
Get a certificate of good standing
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160969369
The content is confirmed! IoT 4.0 and Noveda Technologies!
https://www.otcmarkets.com/stock/IDGC/news/ID-Global-Corp-Announces-Corporate-Update-Management-Structure-after-Acquisition-by-Liberty-Capital-Group-of-San-Diego?id=228525
https://www.otcmarkets.com/stock/IDGC/news/IDGC-Completes-Strategic-Investment-In-Noveda-Technologies?id=233617
Liberty Capital Group. has the leadership position! Idglobal corporation subsidiaries is Farallon, inc., Prestige Liquids, LLC and Noveda Technologies, Inc.
Makes Idglobal also profit on Farallon, Inc.? Please review! They have a great many contracts.
https://govtribe.com/vendors/farallon-inc-dot-89wm4
PDF FORMAT!
Select Download FAR Report to review the Representations and Certifications for FARALLON INC. <<<<<<<
Select Download FAR & DFARS Report to review the Representations and Certifications for FARALLON INC. <<<<<<<
https://beta.sam.gov/entity/081494822?keywords=%22Farallon%20Inc.%22&sort=-relevance&index=&is_active=true&page=1&status=active
Incredible!
DEF 14A Filing Date 2014-12-12 https://www.sec.gov/Archives/edgar/data/811779/000114420414073653/v396431_def14a.htm
Dear Stockholder:
You are cordially invited to attend the Annual Meeting of Stockholders of MultiCell Technologies, Inc., a Delaware corporation (the “Company”). The meeting will be held on January 22, 2015, at 1:30 p.m. local time at the offices of Procopio, Cory, Hargreaves & Savitch LLP, One Del Mar, 12544 High Bluff Drive, Suite 300, San Diego, CA 92130, for the following purposes:
1. To elect directors to serve for the ensuing year and until their successors are elected.
2. To ratify the selection by the Audit Committee of the Board of Directors of the Company of Eide Bailly LLP as the Company’s Independent Registered Public Accounting Firm for its fiscal year ending November 30, 2014.
3. To approve an amendment to the Amended and Restated Certificate of Incorporation, as amended, to effect an increase in the number of authorized shares of the Company’s common stock to a total of 10 billion shares.
4. To approve the Company’s 2014 Equity Incentive Plan.
5. To conduct any other business properly brought before the meeting.
These items of business are more fully described in the Proxy Statement accompanying this Notice.
The record date for the Annual Meeting is November 24, 2014. Only stockholders of record at the close of business on that date may vote at the meeting or any adjournment thereof.
Multicell Technologies raised at what price ??? Because of the ...
Fact Number 1:
Form 15-12G Filing Date 2017-01-13 Rule 12g-4(a)(2) [X]
Common Stock, Par Value $0.01 Per Share
https://www.sec.gov/Archives/edgar/data/811779/000149315217000429/form15-12g.htm
Fact Number 2:
Changes to Exchange Act Registration Requirements to Implement Title V and Title VI of the JOBS Act
https://www.sec.gov/info/smallbus/secg/jobs-act-section-12g-small-business-compliance-guide.htm
Fact Number 3:
Eide Bailly LLP says MCET up and down ???
DEF 14A Filing Date 2014-12-12
https://www.sec.gov/Archives/edgar/data/811779/000114420414073653/v396431_def14a.htm
Authorized Shares 10,000,000,000 12/02/2020
https://www.otcmarkets.com/stock/MCET/security
Fact Number 4:
More accurate Granted Patent Drug names are called: IFH15, IFHP.06, IFHP.12, IFHP.24, IFHP.48, IFHP.96 ( CYP1A2, CYP2B6, CYP2C9, CYP3A4! Multicell Technologies Immortalized Hepatocytes Doc Type Granted Patent in US, Europe and Germany! )
Immortalized Human Hepatocyte Cell Lines
[0084]In another preferred embodiment of the present invention, the cell lines proliferate easily in media. Preferably, the cell lines proliferate easily in a serum-free media. More preferably, the cell lines proliferate easily in MFE media (MultiCell Technologies Inc., Providence, R.I., USA; XenoTech, LLC, Lenexa, Kans., USA). https://www.lens.org/lens/patent/167-627-709-236-287/fulltext
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160160735
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160155674
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160156621
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160258239
Fact Number 5:
Multicell is silent about this filing. 2017-01-13 Rule 12g-4(a)(2)
Common Stock, Par Value $0.01 Per Share https://www.sec.gov/Archives/edgar/data/811779/000149315217000429/form15-12g.htm
$MCET Please Read! Great Multicell Technologies Article from Journal of Nanobiotechnology!
Treatment of breast cancer with autophagy inhibitory microRNAs carried by AGO2-conjugated nanoparticles
28 April 2020
Materials and methods
... Ethylenediaminetetraacetic acid (EDTA) disodium salt was purchased from Multicell (U.S.A.)...
https://jnanobiotechnology.biomedcentral.com/articles/10.1186/s12951-020-00615-4
https://jnanobiotechnology.biomedcentral.com/track/pdf/10.1186/s12951-020-00615-4.pdf
$MCET Please Read! Great Multicell Technologies Article from Journal of Nanobiotechnology!
Treatment of breast cancer with autophagy inhibitory microRNAs carried by AGO2-conjugated nanoparticles
28 April 2020
Materials and methods
... Ethylenediaminetetraacetic acid (EDTA) disodium salt was purchased from Multicell (U.S.A.)...
https://jnanobiotechnology.biomedcentral.com/articles/10.1186/s12951-020-00615-4
https://jnanobiotechnology.biomedcentral.com/track/pdf/10.1186/s12951-020-00615-4.pdf
Next Step hit up! Its coming! Market Makers confirm! https://investorshub.advfn.com/MultiCell-Technologies-MCET-2694/
Next Step hit up! Its coming! Market Makers confirm! https://investorshub.advfn.com/MultiCell-Technologies-MCET-2694/
$GSFI Green Stream Holdings Prepares for Major 2021 Growth with Appointment of New CEO James C. DiPrima
Newsfile Corp.
Newsfile Corp
Malibu, California--(Newsfile Corp. - January 28, 2021) - Green Stream Holdings Inc. (OTC Pink: GSFI) ("the Company") ("Green Stream") (http://www.GreenRainSolar.com), an emerging leader in the solar utility and finance space, is pleased to announce the appointment of Mr. James C. DiPrima as the new corporate Chief Executive Officer.
Green Stream Holdings
To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6720/73027_0e518535b4f65845_002full.jpg
The global solar energy market is projected to grow at an average of 20% per year, surpassing $220 billion by 2026, according to Allied Market Research.
Mr. James C. DiPrima has a Bachelor of Science in Business Administration from Creighton University, Omaha, Nebraska. His career includes 40 years of finance and accounting in both the public and private sectors beginning his career at Deloitte & Touche. He has held various positions with start-up companies, was comptroller of a manufacturing company, founded and operated an accounting and tax consulting firm focused on medical practice management and investment and tax planning. He has served as chief executive officer of MBD Midwest, a holding company for national pack and ship franchises where he managed the development of retail outlets in multiple states. Mr. DiPrima was founder and President of a construction company providing various services to the United States Postal Services.
Mr. DiPrima has been working in various positions with publicly traded companies since 1995. His accomplishments included guiding several companies through the reverse merger process, raising capital and consulting on various mezzanine financings. Most recently he has served as CEO of PAO Group, Inc. a publicly traded holdings company dedicated to operating businesses within the medical cannabis sector focused on medical research and the development of treatments derived from its patented cannabis extraction process. He has also served as CFO for Solar Integrated Roofing, Inc. a public traded company that provides residential solar energy solutions in southern California. Additionally, Mr. DiPrima provides various financial services to micro-cap publicly traded companies on a contract basis.
"Green Stream's recent press highlights the move to New York City as the solar utility services ramp in 2021. We are excited to bring Mr. James C. DiPrima on board to take the helm. His intimate knowledge of the public market space along with strong solar industry experience makes him the perfect candidate to fulfill our business plans moving forward," stated outgoing CEO Eric Fain.
"I am eager to expand the already existing opportunities that Green Stream's innovative solutions will provide to commercial solar energy markets on the East Coast. There is unlimited potential in this segment of the renewable energy space," commented James C. DePrima, CEO.
GSFI - Strategic Moves
To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6720/73027_0e518535b4f65845_003full.jpg
https://www.otcmarkets.com/stock/GSFI/news/story?e&id=1795847
$GSFI Green Stream Holdings Prepares for Major 2021 Growth with Appointment of New CEO James C. DiPrima
Newsfile Corp.
Newsfile Corp
Malibu, California--(Newsfile Corp. - January 28, 2021) - Green Stream Holdings Inc. (OTC Pink: GSFI) ("the Company") ("Green Stream") (http://www.GreenRainSolar.com), an emerging leader in the solar utility and finance space, is pleased to announce the appointment of Mr. James C. DiPrima as the new corporate Chief Executive Officer.
Green Stream Holdings
To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6720/73027_0e518535b4f65845_002full.jpg
The global solar energy market is projected to grow at an average of 20% per year, surpassing $220 billion by 2026, according to Allied Market Research.
Mr. James C. DiPrima has a Bachelor of Science in Business Administration from Creighton University, Omaha, Nebraska. His career includes 40 years of finance and accounting in both the public and private sectors beginning his career at Deloitte & Touche. He has held various positions with start-up companies, was comptroller of a manufacturing company, founded and operated an accounting and tax consulting firm focused on medical practice management and investment and tax planning. He has served as chief executive officer of MBD Midwest, a holding company for national pack and ship franchises where he managed the development of retail outlets in multiple states. Mr. DiPrima was founder and President of a construction company providing various services to the United States Postal Services.
Mr. DiPrima has been working in various positions with publicly traded companies since 1995. His accomplishments included guiding several companies through the reverse merger process, raising capital and consulting on various mezzanine financings. Most recently he has served as CEO of PAO Group, Inc. a publicly traded holdings company dedicated to operating businesses within the medical cannabis sector focused on medical research and the development of treatments derived from its patented cannabis extraction process. He has also served as CFO for Solar Integrated Roofing, Inc. a public traded company that provides residential solar energy solutions in southern California. Additionally, Mr. DiPrima provides various financial services to micro-cap publicly traded companies on a contract basis.
"Green Stream's recent press highlights the move to New York City as the solar utility services ramp in 2021. We are excited to bring Mr. James C. DiPrima on board to take the helm. His intimate knowledge of the public market space along with strong solar industry experience makes him the perfect candidate to fulfill our business plans moving forward," stated outgoing CEO Eric Fain.
"I am eager to expand the already existing opportunities that Green Stream's innovative solutions will provide to commercial solar energy markets on the East Coast. There is unlimited potential in this segment of the renewable energy space," commented James C. DePrima, CEO.
GSFI - Strategic Moves
To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6720/73027_0e518535b4f65845_003full.jpg
https://www.otcmarkets.com/stock/GSFI/news/story?e&id=1795847
Please read! Multicell Technologies has the money, gives the money to Eide Bailly LLP, Eide Bailly LLP buys shares and it goes up. Or! Multicell Technologies needs money, Eide Bailly LLP is selling shares and the price is falling.
$MCET Great Income per year! Look here! https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161288888